Skip to content

Xinju Xiaogao Prescription Study on Overweight

Xinju Xiaogao Prescription and 10% of it in the Treatment of Adiposity (Stagnation of QI Causing Phlegm Retention)Clinical Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01142076
Acronym
XJXG
Enrollment
140
Registered
2010-06-11
Start date
2010-06-30
Completion date
2011-03-31
Last updated
2013-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight

Keywords

adiposity

Brief summary

Xinju Xiaogao prescription and 10% of it in the treatment of adiposity (stagnation of QI causing phlegm retention)clinical study

Detailed description

Charged by the three research centers in line with traditional Chinese medicine stagnation of QI causing phlegm retention 120 cases have diabetes were randomly divided into Chinese herbal compound Xinju Xiaogao prescription group and 10% of the prescription group.The treatment groups were compared 24-week step-down and regulation of body weight,waistline, blood lipids, blood sugar effect.

Interventions

DRUGXinju Xiaogao Prescription

treatment group

DRUGplacebo

Therapeutic dose of 10%

Sponsors

China-Japan Friendship Hospital
CollaboratorOTHER
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
CollaboratorOTHER
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Aged 18-60 years old * BMI≥28kg/m2,but\<40kg/m2 * Waistline≥85cm(male),≥80cm(female) * Pathoglycemia must fulfill one of those four condition: * IGT,7.8≤2hPG≤11.0mmol/, * diabetics take medicine used to treat type 2 diabetes more than 3 month,and 5.6≤FBG≤12.2,and weight change under 4kg. * stagnation of QI causing phlegm retention * To sign informed consent.

Exclusion criteria

* After 3-6 months simply controlling their diet and more exercise treatment, body weight weight loss ≥ 5%. * TG\>4.5mmol/L. * Suffering from congenital heart disease, rheumatic heart disease, kidney disease, serious active liver disease, peptic ulcer disease or malabsorption syndrome. * There is a history of pancreatitis or endocrine diseases other than diabetes, diabetes treated with insulin. * Not suffered myocardial infarction in Past 3 months or unstable angina were confirmed. * Had been diagnosed as post-surgical adhesions . * There is a history of appetite or abuse of laxatives * Diastolic blood pressure,uncontrolled or controlled, three times greater than 105mmHg . * Pregnancy, prepare to pregnant or lactating women prepare. * Allergies to Chinese medicine , allergic. * Recurrent gallstone or a history of kidney stones. * Mentally ill. * Cancer patients. * A history of gastrointestinal surgery to lose weight. * Receiving other clinical studies nearly 3 months. * Alcohol and / or psychoactive substances, drug abusers and addicts. * Taking other weight-reducing aid Close within one month

Design outcomes

Primary

MeasureTime frame
waistlineup to 24 weeks

Secondary

MeasureTime frame
Body Mass Index (BMI)up to 24 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026